Evidence map›Paper›PMID 33374610›Full record

ArticleDiseases (Basel, Switzerland)2020

Outcomes of Kidney Transplantation in Fabry Disease: A Meta-Analysis.

Maria L Gonzalez Suarez, Charat Thongprayoon, Panupong Hansrivijit, Juan Medaura, Pradeep Vaitla, Michael A Mao, Tarun Bathini, Boonphiphop Boonpheng, Swetha R Kanduri, Karthik Kovvuru and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diseases (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Observational
  4. Review
  5. Monogenic Kidney Diseases in Kidney Transplantation.Kidney international reports · 2024
    Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 1 country.

Maria L Gonzalez SuarezDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Charat ThongprayoonDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Panupong HansrivijitDepartment of Internal Medicine, UPMC Pinnacle, Harrisburg, PA 17105, USA.ORCID 0000-0002-5041-4290
Juan MedauraDivision of Nephrology, Department of Internal Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA.ORCID 0000-0001-7746-1612
Pradeep VaitlaDivision of Nephrology, Department of Internal Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA.ORCID 0000-0001-5234-6722
Michael A MaoDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Jacksonville, FL 32224, USA.ORCID 0000-0003-1814-7003
Tarun BathiniDepartment of Internal Medicine, University of Arizona, Tucson, AZ 85721, USA.
Boonphiphop BoonphengDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Swetha R KanduriDivision of Nephrology, Ochsner Medical Center, New Orleans, LA 70121, USA.ORCID 0000-0002-7190-6665
Karthik KovvuruDivision of Nephrology, Ochsner Medical Center, New Orleans, LA 70121, USA.ORCID 0000-0003-2640-724X
Arpita BasuEmory Transplant Center and Department of Medicine, Renal Division, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0002-0533-4582
Wisit CheungpasitpornDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0001-9954-9711
Mayo Clinic · USOchsner Medical Center · USUniversity of Mississippi Medical Center · USEmory University · USMayo Clinic in Florida · USUniversity of Arizona · USUniversity of California, Los Angeles · USUPMC Central Pa · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFabry disease (FD) is a rare X-linked lysosomal storage disorder with progressive systemic deposition of globotriaosylceramide, leading to life-threatening cardiac, central nervous system, and kidney disease. Current therapy involves symptomatic medical management, enzyme replacement therapy (ERT), dialysis, kidney transplantation, and, more recently, gene therapy. The aim of this systematic review was to assess outcomes of kidney transplantation among patients with FD.

methodsA comprehensive literature review was conducted utilizing MEDLINE, EMBASE, and Cochrane Database, from inception through to 28 February 2020, to identify studies that evaluate outcomes of kidney transplantation including patient and allograft survival among kidney transplant patients with FD. Effect estimates from each study were extracted and combined using the random-effects generic inverse variance method of DerSimonian and Laird.

resultsIn total, 11 studies, including 424 kidney transplant recipients with FD, were enrolled. The post-transplant median follow-up time ranged from 3 to 11.5 years. Overall, the pooled estimated rates of all-cause graft failure, graft failure before death, and allograft rejection were 32.5% (95%CI: 23.9%-42.5%), 14.5% (95%CI: 8.4%-23.7%), and 20.2% (95%CI: 15.4%-25.9%), respectively. In the sensitivity analysis, limited only to the recent studies (year 2001 or newer when ERT became available), the pooled estimated rates of all-cause graft failure, graft failure before death, and allograft rejection were 28.1% (95%CI: 20.5%-37.3%), 11.7% (95%CI: 8.4%-16.0%), and 20.2% (95%CI: 15.5%-26.0%), respectively. The pooled estimated rate of biopsy proven FD recurrence was 11.1% (95%CI: 3.6%-29.4%), respectively. There are no significant differences in the risks of all-cause graft failure (

conclusionsDespite possible FD recurrence after transplantation of 11.1%, allograft and patient survival are comparable among kidney transplant recipients with vs. without FD.

Indexed as

Fabry diseasekidney transplantkidney transplantationmeta-analysissystematic review

Identifiers

PMID33374610
PMCPMC7838795
OpenAlexW3114622080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.